IMNN
Imunon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.34
−2.90%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.40
From 52W high−75.37%
Volume47490.00
Market cap$7.52M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.40
From 52W high
−75.37%
Volume
47490.00
Market cap
$7.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
34.7
MomentumView details →
1D Return
−2.90%
YTD Return
−62.99%
SummaryUpdated Jun 1, 2026
Imunon, Inc. (NASDAQ:IMNN) is a clinical-stage biotechnology company founded in 1982 and headquartered in Lawrenceville, New Jersey. Originally known as Celsion Corporation, the company rebranded to Imunon in September 2022 to better reflect its focus on immunotherapy development. The company has been publicly traded since 1999 and specializes in developing DNA-based immunotherapies and vaccines for cancer treatment and infectious diseases. Imunon operates two primary technology platforms and is currently advancing its lead ovarian cancer treatment through Phase III clinical trials while exploring partnerships for its vaccine technologies.
Similar companies
Latest newsMore news →
Imunon entered a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program to advance clinical development of IMNN-001 in new indications and combination regimens.10d agoImunon, Inc. reported a net loss of $2.8 million for Q2 2026, with a diluted loss per share of $0.54, and provided updates on its clinical studies including OVATION 2 and OVATION 3 trials for IMNN-001.41d ago